School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA.
Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Curr Top Microbiol Immunol. 2024;445:109-125. doi: 10.1007/82_2021_250.
Gonorrhea rates and antibiotic resistance are both increasing. Neisseria gonorrhoeae (Ng) is an exclusively human pathogen and is exquisitely adapted to its natural host. Ng can subvert immune responses and undergoes frequent antigenic variation, resulting in limited immunity and protection from reinfection. Previous gonococcal vaccine efforts have been largely unsuccessful, and the last vaccine to be tested in humans was more than 35 years ago. Advancing technologies and the threat of untreatable gonorrhea have fueled renewed pursuit of a vaccine as a long-term sustainable solution for gonorrhea control. Despite the development of a female mouse model of genital gonococcal infection two decades ago, correlates of immunity or protection remain largely unknown, making the gonococcus a challenging vaccine target. The controlled human urethral infection model of gonorrhea (Ng CHIM) has been used to study gonococcal pathogenesis and the basis of anti-gonococcal immunity. Over 200 participants have been inoculated without serious adverse events. The Ng CHIM replicates the early natural course of urethral infection. We are now at an inflexion point to pivot the use of the model for vaccine testing to address the urgency of improved gonorrhea control. Herein we discuss the need for gonorrhea vaccines, and the advantages and limitations of the Ng CHIM in accelerating the development of gonorrhea vaccines.
淋病发病率和抗生素耐药率均呈上升趋势。淋病奈瑟菌(Ng)是一种专性人类病原体,对其自然宿主具有高度适应性。Ng 可以颠覆免疫反应,并经历频繁的抗原变异,导致有限的免疫力和防止再次感染的保护。以前的淋病疫苗研究工作大多没有成功,最后一次在人类身上测试的疫苗是在 35 年多前。先进的技术和无法治疗的淋病的威胁,促使人们重新寻求疫苗作为淋病控制的长期可持续解决方案。尽管二十年前已经开发出了一种用于研究生殖道淋病感染的雌性小鼠模型,但对免疫或保护的相关性仍知之甚少,这使得淋球菌成为一个具有挑战性的疫苗靶标。淋病奈瑟菌控制的人体尿道感染模型(Ng CHIM)已被用于研究淋病奈瑟菌的发病机制和抗淋病奈瑟菌免疫的基础。已有超过 200 名参与者接种了该模型,没有发生严重的不良事件。Ng CHIM 复制了尿道感染的早期自然病程。我们现在正处于一个转折点,即将该模型用于疫苗测试,以应对改善淋病控制的紧迫性。本文讨论了淋病疫苗的必要性,以及 Ng CHIM 在加速淋病疫苗开发方面的优势和局限性。